Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst
1. Eli Lilly to raise Mounjaro price by 170% in the U.K. 2. Price hikes aim to align with European market standards. 3. Analysts expect similar price increases across Europe soon. 4. BofA maintains Buy rating with a $900 price target. 5. Investor apprehension rising amid competition with Novo Nordisk.